Main Article Content
Background: Improving the awareness of the public about the body weight and the body mass index (BMI) criteria is very important as increased body weight may be associated with an increased risk for many dangerous diseases and health complications. Propranolol is generally prescribed for tachycardia while its most common side effects are bradycardia and masking hypoglycemia.
Case Presentation: A tachycardia was diagnosed in a young overweight woman and treated successfully with propranolol but this treatment, unpredictably, was associated with a rapid increase in the weight that classified her as obese.
Discussion: The physical (body weight and heart rate) and the biochemical (blood glucose level) monitoring and analysis including the lifestyle provided a deeper insight into the principal details and helped to design a personalized treatment protocol.
Conclusion: A therapeutic dose of propranolol could be linked to uncommon mounting weight change which was associated with a decrease in the blood glucose level and an appetite enhancement.
Lee JM, Gebremariam A, Vijan S, Gurney JG. Excess body mass index-years, a measure of degree and duration of excess weight, and risk for incident diabetes. Arch Pediat Adol Med. 2012;166(1):42–48.
Kearney PM, Whelton M, Reynolds K, Whelton PK, He J. Worldwide Prevalence of Hypertension: a Systematic Review. J Hypertens. 2004;22(1):11-19.
Barrouq DMS, Irshaidat T. Meal plan prescription, biochemical parameters, and practicality in poorly controlled type-II diabetes mellitus patients. Int J Adv Med. 2020;7(9):1331-1338.
Freire RH. Alvarez-Leite JI. Appetite control: Hormones or diet strategies? Curr Opin Clin Nutr Metab Care. 2020;23(5):328-335.
Cheskin LJ, Bartlett SJ, Zayas R, Twilley CH, Allison DB, Contoreggi C. Prescription medications: a modifiable contributor to obesity. South Med J. 1999;92(9):898-904.
Samani EK. The association between therapeutic drug classes and weight change in patients attending a medically supervised weight loss clinic. Thesis, York University, Canada; 2017.
Wharton S, Raiber L, Serodio KJ, Lee J, Christensen RAG. Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes Metab Syndr Obes. 2018;11:427–438.
Qureshi1 NA, Al-Dossari DS, Salem SO, Alkhamees OA, Alsanad SM. Psychotropic medication-induced weight gain or loss looked through the lens of age and psychiatric diagnoses: A narrative review. Int Neuropsychiatr Dis J. 2018;11(3):1-30.
Barrouq DMS, Irshaidat T. Novel Association between Gemfibrozil and Dyslipidemia: A Case Report. Asian J Med Health. 2020;18(10):38-43.
Lucido CT, Miskimins WK, Vermeer PD. Propranolol promotes glucose dependence and synergizes with dichloroacetate for anti-cancer activity in HNSCC. Cancer. 2018;10:476-492]
Kalam MN, Rasool MF, Rehman A, Ahmed N. Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review. Current Drug Metabolism. 2020;21(2):89-105.
Rössner S, Taylor CL, Byington RP, Furberg CD. Long term propranolol treatment and changes in body weight after myocardial infarction. BMJ. 1990;300(6729):902-903.
Alves-Wagner AB, Mori RC, Sabino-Silva R, Fatima LA, Alves AS, Britto LR, Schaanc BD, Machadoa UF. Beta-adrenergic blockade increases GLUT4 and improves glycemic control in insulin-treated diabetic Wistar rats. Auton. Neurosci 2015;193:108-116.
Barrouq DMS, Irshaidat T. Tachycardia, Diabetes, And Illness Psychology Interplay At The Edge: A Case Report. Int J Med Biomed Stud. 2020;4(8):70-72.
Berthoud HR, Münzberg H, Morrison CD. Blaming the brain for obesity: Integration of hedonic and homeostatic mechanisms. Gastroenterology. 2017;152:1728–1738.